Novartis Ag

Novartis Pharmaceuticals Corporation

Novartis Pharma Ag

Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research

Novartis Pharma Gmbh

Terence O'Reilly

Markus Wartmann

Heidi Lane

Jeanette Marjorie Wood

Pamela Cohen

Manuel Litchman

Carl-Henrik Heldin

Peter Traxler

John David Rothermel

Ralf Brandt

Elisabeth Buchdunger

Kristian Pietras

George Thomas

Arne Östman

Anne Boulay

Iwan Beuvink

The present invention is directed to the use of rapamycin derivatives for use in treating solid tumors, optionally in combination with a chemotherapeutic agent.

Treatment of solid tumors with rapamycin derivatives

Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.

Rapamycin derivatives have interesting effects in the treatment of solid tumors, optionally in combination with a chemotherapeutic agent.

Cancer treatment

The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.

Cancer treatment with epothilones

Provided are biomarkers for determining the sensitivity of proliferative diseases such as cancer to therapeutic agents, in particular mTOR inhibitors in combination with a cytotoxic agent, in particular a cytotoxic agent which damages or affects the integrity of DNA.

p53 wild-type as biomarker for the treatment with mTOR inhibitors in combination with a cytotoxic agent

The present invention relates to a combination comprising N-{5-[4-(4-methyl-piperazino-methyl) -benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and an epothiione derivative; pharmaceutical composition comprising said combination; method of treatment comprising said combination; and commercial packages comprising said combination.

Combination comprising a signal transduction inhibitor and an epothilone derivative

Growing community of inventors

Basel, Switzerland

Terence O'Reilly